ZACHARY RUSSO: Open Payments
NPI 1679194633 · NEW BRITAIN, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$639 in 52 payments from 9 companies in 2025. Trend: 2023 $0 · 2024 $226 · 2025 $639
Food & beverage: $639
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 32 | $290 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $76 |
| Axsome Therapeutics, Inc. | 3 | $70 |
| Janssen Pharmaceuticals, Inc | 3 | $61 |
| Vanda Pharmaceuticals Inc. | 3 | $52 |
| Otsuka America Pharmaceutical, Inc. | 3 | $44 |
| Collegium Pharmaceutical, Inc. | 1 | $16 |
| Alkermes, Inc. | 1 | $16 |
| Neurocrine BioSciences, Inc. | 1 | $14 |
Products named: VRAYLAR, CAPLYTA, Auvelity, FANAPT, INVEGA SUSTENNA, ABILIFY MAINTENA, SPRAVATO, Jornay PM.
Industry payments across CT — which companies pay providers there.
